AUTHORS
Jordi Esteve, MD, PhD, Sebastian Zaruma2, Ana Triguero3, Mi Kwon , MD, PhD4, Gabriela Rodriguez-Macias, MD, PhD5, Montserrat Arnan Sangerman Sr, PhD6, Rosa Coll Sr, Hematologist7, Ferran Vall-Llovera Calmet8, Mar Tormo Sr, MD9, Antonio Garcia-Guiñon10, Susana Vives, MD11, Sara Garcia-Avila12, Javier Diaz-Carbonero, MD13, Helena Pomares Sr, MD, PhD14, Antonia Sampol Mayol, MD15, Luiz Andre Aguilar16, Rubén Gómez de Antonio Jr, MD17, Olga Salamero Sr18, Antonia Cladera Serra19, Alexandra Martínez-Roca20, Albert Cortés-Bullich21, Juan Jose Rodriguez-Sevilla22, Ines Zugasti Asin23, Marina Cornejo24, Guadalupe Oñate Sr25, Lurdes Zamora, PhD26, Francesca Guijarro, MD27, Monica Lopez-Guerra28, Marta Pratcorona Canela29, Ana Garrido Diaz30, Marina Díaz-Beyá31
AFFILIATIONS
1 August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain, Hospital Clínic De Barcelona, Barcelona, Spain, University of Barcelona, Barcelona, Spain
2 MFAR, Barcelona, Spain
3 August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain, Hospital Clínic De Barcelona, Barcelona, Spain
4 Hospital Gregorio Marañón, Madrid, Spain
5 Hospital Gregorio Marañón, Madrid, Spain
6 ICO Duran i Reynals, Hospitalet de Llobregat, Spain
7 ICO Hospital Josep Trueta, Girona, Spain
8 Hospital Universitari Mútua de Terrassa, Terrassa, Spain
9 Hospital Clínico Universitario, Valencia, Spain, Instituto de Investigación Biomedicina INCLIVA, Valencia, Spain
10 Hospital Arnau de Vilanova, Lleida, Spain
11 ICO Badalona-Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Badalona, Spain
12 Hospital del Mar, Barcelona, Spain
13 ICO Duran i Reynals, Hospitalet de Llobregat, Spain
14 ICO Duran i Reynals, Hospitalet de Llobregat, Spain
15 Hospital Son Espases, Palma de Mallorca, Spain
16 ICO- Hospital Joan XXIII, Tarragona, Spain
17 ICO Duran i Reynals, Hospitalet de Llobregat, Spain
18 Hospital Universitari Vall d’Hebron, VHIO, Barcelona, Spain
19 Hospital de Son Llàtzer, Palma de Mallorca, Spain
20 August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain, Hospital Clínic De Barcelona, Barcelona, Spain
21 August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain, Hospital Clínic De Barcelona, Barcelona, Spain
22 August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain, Hospital Clínic De Barcelona, Barcelona, Spain
23 August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain, Hospital Clínic De Barcelona, Barcelona, Spain
24 August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain, Hospital Clínic De Barcelona, Barcelona, Spain
25 Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
26 ICO Badalona-Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Badalona, Spain
27 August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain, Hematopathology Unit, Hospital Clínic of Barcelona, Barcelona, Spain
28 August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain, Hematopathology Unit, Hospital Clínic of Barcelona, Barcelona, Spain
29 Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
30 Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
31 August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain, Hospital Clínic De Barcelona, Barcelona, Spain
ABSTRACT
Background: Measurable residual disease (MRD) status at pre-specified time-points constitutes one of the strongest prognostic factors for survival in patients with AML treated with intensive chemotherapy (ICT). Accordingly, several studies have explored preemptive interventions aimed at preventing hematologic relapse after MRD persistence or relapse (R/R MRD), including few recent prospective trials. However, the ability of MRD-driven interception to overcome the adverse prognosis associated with R/R MRD remains unproved.
In this context, we designed a prospective phase 2 trial of preemptive treatment with azacytidine plus venetoclax (AzaVen) in patients with R/R MRD after frontline ICT. The primary objective of this trial was MRD eradication, with the ultimate goal of improving long-term outcome.
Patients and Methods: The VERDI study (CETLAM-LMA-AC-2024-01; NCT06668558) is an investigator-initiated, multicenter, multicohort, phase II trial with combination of VenAza for patients failing to achieve or maintain MRD negativity (MRD failure) following ICT. MRD failure was defined according to MRD ELN 2021 consensus criteria. Patients were recruited in two independent cohorts:
Cohort 1: Patients with a favorable ELN 2017 subtype AML, not planned for allogeneic hematopoietic cell transplantation (alloHCT) in first complete remission (CR1), with MRD failure after frontline ICT.
Cohort 2: Patients with a non-favorable ELN 2017 AML subtype, planned to proceed to alloHCT in CR1, with detectable high level MRD burden (defined as >0.1%) before alloHCT.
Treatment consisted of 2 to 4 VenAza cycles. Patients achieving an MRD reduction after cycle 2 (C2) could receive up to two additional cycles. MRD response was defined as either MRD eradication or >1-log reduction in patients achieving low level MRD (Cloos J, et al. Blood 2026). AlloHCT was recommended for all patients following study treatment; however, patients in cohort 1 who achieved MRD eradication after VenAza could continue treatment for up to 12 cycles at the investigator’s discretion.
Results: Twenty-eight patients were enrolled (median age, 55.5 years [range, 18–70]; 12 female (43%) and 16 male), 14 in each cohort. In cohort 1, 10 patients (71%) were diagnosed with AML with NPM1 mutation (NPM1m AML), while the remaining patients correspond to CBF-rearranged AML (CBFr AML). In cohort 2, most patients (n=9, 64%) were diagnosed with a myelodysplasia-related AML.
Median number of administered cycles was 2 (1-8), 3 (1-8) in cohort 1 and 2 (1-3) in cohort 2. Neutropenia was the most frequent treatment related adverse event (AE), observed in 19 (68%) patients (grade 3-4 (G3-4) in all), followed by thrombocytopenia in 11 (39%: G3-4 in 7). Neutropenia-related G3-4 infections, however, were observed only in 2 patients (7%). No patient discontinued treatment due to treatment-related AEs.
In cohort 1, 10/14 (71%) patients achieved an MRD response after intervention (8/10 NPM1m AML, 2/4 CBFr AML). Seven patients underwent alloHCT after study treatment. At last follow-up, 11/14 patients maintained MRD response (achieved in 3 of them after alloHCT), and only one patient relapsed after preemptive intervention.
In cohort 2, 7/14 (50%) patients achieved an MRD response after treatment trial. One patient progressed rapidly after only one cycle. Ten patients underwent alloHCT after preemptive intervention, and 3 of them eradicated MRD after transplant. At last follow, 8 patients remained in MRD-negative status, 1 died after alloHCT due to a non-relapse related cause, and 5 patients experienced relapse.
After a median follow-up of 9 months, overall 1-year survival and relapse-free survival (RFS) after intervention was 75.6% (95% CI: 59.1-96.7) and 66.8% (95% CI:50 – 89.2), respectively, with a significantly better RFS in cohort 1 (1-yr RFS: 93% vs. 44.2%; log-rank test, p=0.016).
Conclusions: A MRD-driven interception strategy with VenAza was feasible and tolerable in patients developing MRD failure after frontline ICT, with a low risk of hematologic progression during preemptive treatment. The outcome after MRD-driven intervention was strongly associated with AML subtype, with ELN favorable risk patients obtaining a higher benefit from this VenAza-based preemptive intervention. These findings support the feasibility of MRD-directed interception and highlight the need for alternative preemptive strategies for patients who fail to achieve MRD eradication after ICT.
DISCLOSURES
Jordi Esteve, MD, PhD: Jazz Pharmaceuticals - Research Funding; Abbvie - Research Funding; Astellas - Consultancy (Includes expert testimony); Menarini Stemline - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Jazz Pharmaceuticals - Consultancy (Includes expert testimony)